Table 3.
Comparison of clinical factors in 305 patients with soft tissue sarcoma in respect to detailed resection margins.
| Contaminated | <1mm | 1–5 mm | >5 mm | >10 mm | All | |
|---|---|---|---|---|---|---|
| All patients | 31 (10.2%) | 64 (21%) | 123 (40.3%) | 47 (15.4%) | 40 (13.1%) | 305 (100%) |
| Age | ||||||
| <60 years | 13 (9.8%) | 21 (15.8%) | 54 (40.6%) | 24 (18.0%) | 21 (15.8%) | 133 (43.4%) |
| ≥60 years | 18 (10.5%) | 43 (25.0%) | 69 (40.1%) | 23 (13.4%) | 19 (11.0%) | 172 (56.4%) |
| Sex | ||||||
| Female | 11 (7.8%) | 30 (21.3%) | 63 (44.7%) | 20 (14.2%) | 17 (12.1%) | 141 (46.2%) |
| Male | 20 (12.2%) | 34 (20.7%) | 60 (36.6%) | 27 (16.5%) | 23 (14.0%) | 164 (53.8%) |
| Tumor size | ||||||
| <5 cm | 3 (2.4%) | 15 (11.8%) | 55 (43.3%) | 33 (26.0%) | 21 (16.5%) | 128 (42.0%) |
| ≥5 cm | 28 (15.8%) | 49 (27.7%) | 68 (38.4%) | 14 (7.9%) | 18 (10.2) | 177 (58.0%) |
| Location | ||||||
| Upper extremity | 10 (13.9%) | 17 (23.6%) | 26 (36.1%) | 9 (12.5%) | 10 (13.9%) | 72 (23.6%) |
| Trunk/pelvis | 2 (4.8%) | 6 (14.3%) | 15 (35.7%) | 10 (23.8%) | 9 (21.4%) | 42 (13.8%) |
| Lower extremity | 19 (9.9%) | 41 (21.5%) | 82 (42.9%) | 28 (14.7%) | 21 (11.0%) | 191 (62.6%) |
| UPS histology | ||||||
| Yes | 9 (7.4%) | 24 (19.8%) | 58 (47.9%) | 18 (14.9%) | 12 (9.9%) | 121 (39.7%) |
| No | 22 (12.0%) | 40 (21.7%) | 65 (35.3%) | 29 (15.8%) | 28 (15.2%) | 184 (60.3%) |
| Grading | ||||||
| G2 | 15 (12.4%) | 24 (19.8%) | 44 (36.4%) | 23 (19.0%) | 15 (12.4%) | 121 (39.7%) |
| G3 | 16 (8.7%) | 40 (21.7%) | 79 (42.9%) | 24 (13.0%) | 25 (13.6%) | 184 (60.3%) |
| Radiotherapy | ||||||
| Yes | 23 (10.8%) | 48 (22.6%) | 94 (44.3%) | 34 (16.0%) | 13 (6.1%) | 212 (69.5%) |
| No | 8 (8.6%) | 16 (17.2%) | 29 (31.2%) | 13 (14.0%) | 27 (29.0%) | 93 (30.5%) |
| Chemotherapy | ||||||
| Yes | 21 (13.0%) | 36 (22.2%) | 66 (40.7%) | 23 (14.2%) | 16 (9.9%) | 162 (53.1%) |
| No | 10 (7.0%) | 28 (19.6%) | 57 (39.9%) | 24 (16.8%) | 24 (16.8%) | 143 (46.9%) |